Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10698088 | 0.95 | SLC6A9 (0.46) | SLC6A9SLC6A5OPRM1HSD17B10OPRD1 | |
| SCHEMBL5562519 | 0.89 | SLC6A9 (0.48) | SLC6A9SLC6A5OPRM1HSD17B10OPRD1 | |
| SCHEMBL5562296 | 0.79 | HSD17B10 (0.42) | SLC6A9SLC6A5OPRM1HSD17B10OPRD1 | |
| SCHEMBL5849731 | 0.77 | SLC6A9 (0.53) | SLC6A9SLC6A5OPRM1OPRD1OPRK1 | |
| SCHEMBL7637063 | 0.73 | DRD2 (0.42) | SLC6A9SLC6A5OPRM1HSD17B10 | |
| SCHEMBL11336683 | 0.73 | SLC6A9 (0.57) | SLC6A9SLC6A5OPRM1 | |
| SCHEMBL16883674 | 0.73 | HSD17B10 (0.51) | OPRM1HSD17B10OPRD1OPRK1OPRL1 | |
| SCHEMBL13543075 | 0.72 | SLC6A9 (0.58) | SLC6A9SLC6A5OPRM1HSD17B10OPRD1 | |
| Hydrochloric Acid SCHEMBL30686618 | 0.72 | HSD17B10 (0.50) | OPRM1HSD17B10OPRD1OPRK1OPRL1 | |
| SCHEMBL2452166 | 0.70 | SMN1; SMN2 (0.36) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071195-B2 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L | 2006-03-09 | — | — | US | disclosed |
| US-6987188-B2 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT | 2006-01-17 | — | — | US | disclosed |
| EP-1202986-B1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT (US) | 2005-03-10 | — | — | US | disclosed |
| US-6841552-B1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1493742-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1202986-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1177172-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001009120-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000068197-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-4411904-A | Diphenylpropanamines, compositions thereof and use thereof | WARNER-LAMBERT COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4292321-A | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof | WARNER-LAMBERT COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | SLC6A9 2863/4885SLC6A5 1007/4885OPRM1 135/4885 |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | NPY1R, NPY4R, NPY2R | SLC6A9 1534/4885SLC6A5 2902/4885OPRM1 140/4885 |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | SLC6A9 3038/4885SLC6A5 1047/4885OPRM1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.